Analyst Price Targets — OPRX
Latest News for OPRX
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor.
AWM Investment Company Inc. acquired a new stake in OptimizeRx Corp. (NASDAQ: OPRX) in the undefined quarter, according to the company in its most recent filing with the SEC. The firm acquired 240,421 shares of the company's stock, valued at approximately $1,375,000. AWM Investment Company Inc. owned about 1.28% of OptimizeRx as of
Dimensional Fund Advisors LP grew its position in shares of OptimizeRx Corp. (NASDAQ: OPRX) by 22.3% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 563,570 shares of the company's stock after buying an additional 102,661 shares during the
OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OPRX.
U.S. House Trading
No House trades found for OPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.